Galimedix Therapeutics to Participate in the 8th Annual Glaucoma 360 Conference KENSINGTON, Md. and SHORASHIM, Israel, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, today announced its...

Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the...

New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects “Hot Topics” Poster at Society for Neuroscience Conference Suggests Even Highly Diluted Concentrations of MRZ-99030 Prevented Formation of Toxic Amyloid Beta Oligomers KENSINGTON, Md. and SHORASHIM,...

New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects “Hot Topics” Poster at Society for Neuroscience Conference Suggests Even Highly Diluted Concentrations of MRZ-99030 Prevented Formation of Toxic Amyloid Beta Oligomers KENSINGTON, Md. and SHORASHIM,...